Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat M. Price, Eric O. Aboagye

    Research output: Contribution to journalArticlepeer-review


    Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.
    Original languageEnglish
    Pages (from-to)917-929
    Number of pages12
    JournalCurrent Pharmaceutical Design
    Issue number11
    Publication statusPublished - 2003


    • pharmacokinetics: Acridines
    • Animals
    • chemistry: Antineoplastic Agents
    • analogs & derivatives: Dacarbazine
    • chemistry: Fluorouracil
    • Humans
    • Molecular Structure
    • Radioactive Tracers
    • chemistry: Radiopharmaceuticals
    • Tissue Distribution
    • Tomography, Emission-Computed


    Dive into the research topics of 'Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography'. Together they form a unique fingerprint.

    Cite this